BioArctic (NASDAQ:B) and its partner Eisai presented significant new data at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) in Copenhagen, highlighted by the first large-scale look at real-world long-term persistence for the Alzheimer's treatment lecanemab.
A claims analysis of 10,763 individuals in the United States showed that 78.4% of patients remained on the intravenous (IV) therapy at 18 months, with 71.7% persisting at 20 months and 67.3% continuing through 24 months.
The retrospective study, which utilized the PurpleLab CLEAR Claims database, indicates that real-world adherence is mirroring the high continuation rates seen in the pivotal Phase 3 Clarity AD clinical trials.
The data revealed a mean dosing interval of 16.4 days, suggesting that patients are largely sticking to the recommended bi-weekly infusion schedule despite the logistical requirements of MRI monitoring and clinical administration.
In addition to the persistence data, BioArctic’s co-founder Professor Lars Lannfelt delivered an oral presentation regarding lecanemab’s unique binding profile.
The research confirmed the antibody’s high selectivity for soluble amyloid-beta (Aβ) protofibrils—the species believed to be the most toxic to neurons—over monomers and fibrils.
This selectivity is a core differentiator for lecanemab and is thought to contribute to its efficacy in slowing cognitive decline while minimizing certain off-target risks.
BioArctic also provided updates on its proprietary pipeline, specifically a poster presentation on exidavnemab, a drug candidate for Parkinson's disease and multiple system atrophy.
The company showcased the successful use of an alpha-synuclein seed amplification assay (SAA) as a screening tool in the ongoing EXIST Phase 2a trial.
This biomarker-driven approach allows for more precise patient stratification, ensuring that participants have the specific protein pathology that exidavnemab is designed to target.